NEW YORK, Sept. 17, 2014 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company") (OTC:NVIV) common stock between April 5, 2013 and August 26, 2013.
Click here to learn about the case: http://docs.wongesq.com/NVIV-Info-Request-Form-372. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period the Company misrepresented the time needed to submit testing data for its biopolymer scaffold product to the Food and Drug Administration. In particular, it is alleged that the Company stated it would be able to report results by the end of 2014 despite conditions set by the FDA that, unbeknownst to investors, would make meeting this deadline impossible.
If you suffered a loss in InVivo you have until October 6, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/NVIV-Info-Request-Form-372.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
